Show simple item record

dc.contributor.authorFortner, Renée T
dc.contributor.authorSchock, Helena
dc.contributor.authorLe Cornet, Charlotte
dc.contributor.authorHüsing, Anika
dc.contributor.authorVitonis, Allison F
dc.contributor.authorJohnson, Theron S
dc.contributor.authorFichorova, Raina N
dc.contributor.authorFashemi, Titilayo
dc.contributor.authorYamamoto, Hidemi S
dc.contributor.authorTjønneland, Anne
dc.contributor.authorHansen, Louise
dc.contributor.authorOvervad, Kim
dc.contributor.authorBoutron-Ruault, Marie-Christine
dc.contributor.authorKvaskoff, Marina
dc.contributor.authorSeveri, Gianluca
dc.contributor.authorBoeing, Heiner
dc.contributor.authorTrichopoulou, Antonia
dc.contributor.authorPapatesta, Eleni-Maria
dc.contributor.authorLa Vecchia, Carlo
dc.contributor.authorPalli, Domenico
dc.contributor.authorSieri, Sabina
dc.contributor.authorTumino, Rosario
dc.contributor.authorSacerdote, Carlotta
dc.contributor.authorMattiello, Amalia
dc.contributor.authorOnland-Moret, N Charlotte
dc.contributor.authorPeeters, Petra H
dc.contributor.authorBueno-de-Mesquita, H B As
dc.contributor.authorWeiderpass, Elisabete
dc.contributor.authorQuirós, J Ramón
dc.contributor.authorDuell, Eric J
dc.contributor.authorSánchez, Maria-Jose
dc.contributor.authorNavarro, Carmen
dc.contributor.authorArdanaz, Eva
dc.contributor.authorLarrañaga, Nerea
dc.contributor.authorNodin, Björn
dc.contributor.authorJirström, Karin
dc.contributor.authorIdahl, Annika
dc.contributor.authorLundin, Eva
dc.contributor.authorKhaw, Kay-Tee
dc.contributor.authorTravis, Ruth C
dc.contributor.authorGunter, Marc
dc.contributor.authorJohansson, Mattias
dc.contributor.authorDossus, Laure
dc.contributor.authorMerritt, Melissa A
dc.contributor.authorRiboli, Elio
dc.contributor.authorTerry, Kathryn L
dc.contributor.authorCramer, Daniel W
dc.contributor.authorKaaks, Rudolf
dc.date.accessioned2018-03-20T14:18:24Z
dc.date.available2018-03-20T14:18:24Z
dc.date.issued2018-04-01
dc.identifier.citationOvarian cancer early detection by circulating CA125 in the context of anti-CA125 autoantibody levels: Results from the EPIC cohort. 2018, 142 (7):1355-1360 Int. J. Canceren
dc.identifier.issn1097-0215
dc.identifier.pmid29159934
dc.identifier.doi10.1002/ijc.31164
dc.identifier.urihttp://hdl.handle.net/10029/621659
dc.description.abstractCA125 is the best ovarian cancer early detection marker to date; however, sensitivity is limited and complementary markers are required to improve discrimination between ovarian cancer cases and non-cases. Anti-CA125 autoantibodies are observed in circulation. Our objective was to evaluate whether these antibodies (1) can serve as early detection markers, providing evidence of an immune response to a developing tumor, and (2) modify the discriminatory capacity of CA125 by either masking CA125 levels (resulting in lower discrimination) or acting synergistically to improve discrimination between cases and non-cases. We investigated these objectives using a nested case-control study within the European Prospective Investigation into Cancer and Nutrition cohort (EPIC) including 250 cases diagnosed within 4 years of blood collection and up to four matched controls. Circulating CA125 antigen and antibody levels were quantified using an electrochemiluminescence assay. Adjusted areas under the curve (aAUCs) by 2-year lag-time intervals were calculated using conditional logistic regression calibrated toward the absolute risk estimates from a pre-existing epidemiological risk model as an offset-variable. Anti-CA125 levels alone did not discriminate cases from controls. For cases diagnosed <2 years after blood collection, discrimination by CA125 antigen was suggestively higher with higher anti-CA125 levels (aAUC, highest antibody tertile: 0.84 [0.76-0.92]; lowest tertile: 0.76 [0.67-0.86]; phet = 0.06). We provide the first evidence of potentially synergistic discrimination effects of CA125 and anti-CA125 antibodies in ovarian early detection. If these findings are replicated, evaluating CA125 in the context of its antibody may improve ovarian cancer early detection.
dc.language.isoenen
dc.rightsinfo:eu-repo/semantics/closedAccessen
dc.titleOvarian cancer early detection by circulating CA125 in the context of anti-CA125 autoantibody levels: Results from the EPIC cohort.en
dc.typeArticleen
dc.identifier.journalInt J Cancer 2018; 142(7):1355-60en
html.description.abstractCA125 is the best ovarian cancer early detection marker to date; however, sensitivity is limited and complementary markers are required to improve discrimination between ovarian cancer cases and non-cases. Anti-CA125 autoantibodies are observed in circulation. Our objective was to evaluate whether these antibodies (1) can serve as early detection markers, providing evidence of an immune response to a developing tumor, and (2) modify the discriminatory capacity of CA125 by either masking CA125 levels (resulting in lower discrimination) or acting synergistically to improve discrimination between cases and non-cases. We investigated these objectives using a nested case-control study within the European Prospective Investigation into Cancer and Nutrition cohort (EPIC) including 250 cases diagnosed within 4 years of blood collection and up to four matched controls. Circulating CA125 antigen and antibody levels were quantified using an electrochemiluminescence assay. Adjusted areas under the curve (aAUCs) by 2-year lag-time intervals were calculated using conditional logistic regression calibrated toward the absolute risk estimates from a pre-existing epidemiological risk model as an offset-variable. Anti-CA125 levels alone did not discriminate cases from controls. For cases diagnosed <2 years after blood collection, discrimination by CA125 antigen was suggestively higher with higher anti-CA125 levels (aAUC, highest antibody tertile: 0.84 [0.76-0.92]; lowest tertile: 0.76 [0.67-0.86]; phet = 0.06). We provide the first evidence of potentially synergistic discrimination effects of CA125 and anti-CA125 antibodies in ovarian early detection. If these findings are replicated, evaluating CA125 in the context of its antibody may improve ovarian cancer early detection.


This item appears in the following Collection(s)

Show simple item record